financetom
Business
financetom
/
Business
/
AMC tops revenue target as box office hits drive strong demand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
AMC tops revenue target as box office hits drive strong demand
Feb 25, 2025 2:40 PM

Feb 25 (Reuters) - AMC Entertainment ( AMC ) topped Wall

Street estimates for quarterly revenue on Tuesday, boosted by

wildly popular releases including "Moana 2" and "Wicked" that

helped draw a strong crowd of moviegoers.

Shares of the company rose about 3% in extended trading

after it reported a 20% jump in attendance in theaters in the

fourth quarter.

AMC's results are another sign Hollywood studios and cinemas

have rebounded from disruptions caused by the strikes in 2023 by

writers and actors, which left theater chains with a thin slate

of releases in the first half of last year.

Disney's ( DIS ) animated musical "Moana 2" debuted with an

estimated $368 million in global ticket sales, and combined with

"Wicked" and "Gladiator II" helped deliver the biggest

Thanksgiving weekend in U.S. and Canadian box office history.

Leawood, Kansas-based AMC said attendance in theaters rose

to 62.4 million, compared with 51.9 million a year earlier.

The strong attendance numbers could also help quell some

fears around the death of cinema, after prolonged closures

during the COVID-19 pandemic sparked concerns audiences might

prefer to stream movies at home rather than heading to theaters.

AMC also generated about $114 million in free cash flow in

the quarter, marking its highest quarterly cash flow post

pandemic.

The company expects to see material growth in the

industry-wide box office in 2025 and beyond, CEO Adam Aron said,

pointing to "a growing lineup of movies (that) open exclusively

in movie theaters".

Revenue for the fourth quarter ended December 31 rose 18% to

$1.31 billion, compared with analysts' average estimate of $1.30

billion according to data compiled by LSEG.

The company reported net loss of $135.6 million, smaller

than the $182 million loss a year earlier.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US lobby group PhRMA plans website to boost access to cheaper drugs
US lobby group PhRMA plans website to boost access to cheaper drugs
Sep 29, 2025
Sept 29 (Reuters) - U.S. pharmaceutical lobby group PhRMA said on Monday it would launch a new website in January to help patients buy prescription drugs directly from manufacturers, bypassing pharmacy benefit managers and other middlemen. The website, to be called AmericasMedicines.com, will allow drugmakers to list medicines available for direct purchase and connect patients with programs that offer lower...
Market Chatter: Irenic Capital Builds Stake in Workiva, Pushes for Board Seats, Possible Sale
Market Chatter: Irenic Capital Builds Stake in Workiva, Pushes for Board Seats, Possible Sale
Sep 29, 2025
10:55 AM EDT, 09/29/2025 (MT Newswires) -- Irenic Capital Management has built a roughly 2% stake in Workiva ( WK ) and is pressing the financial reporting software company to improve operating efficiency, refresh its board, and consider a potential sale, Reuters reported Monday, citing documents and people familiar with the matter. The hedge fund is urging Workiva ( WK...
MoonLake Faces Regulatory Uncertainty After Disappointing Skin Drug Data, Wedbush Says
MoonLake Faces Regulatory Uncertainty After Disappointing Skin Drug Data, Wedbush Says
Sep 29, 2025
10:53 AM EDT, 09/29/2025 (MT Newswires) -- MoonLake Immunotherapeutics ( MLTX ) faces a murky regulatory outlook after late-stage study results for its skin drug sonelokimab disappointed investors, Wedbush said Monday in a note. The trial data appear to suggest inferiority compared with the rival bimekizumab for hidradenitis suppurativa, Wedbush said. Some results in the latest trial also were weaker...
Knorex Ltd Announces Pricing of $12 Million Initial Public Offering
Knorex Ltd Announces Pricing of $12 Million Initial Public Offering
Sep 29, 2025
SUNNYVALE, Calif. and Singapore, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Knorex Ltd. (“Knorex” or the “Company”), a leading provider of AI-driven digital advertising products and solutions, today announced the pricing of its initial public offering of an aggregate of 3,000,000 Class A ordinary shares (the “Shares”), all of which are being offered by Knorex at a public offering price of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved